Glipizide - Generic Drug Details

What are the generic drug sources for glipizide and what is the scope of freedom to operate?

Glipizide is the generic ingredient in five branded drugs marketed by Aurobindo Pharma, Ph Health, Pharmobedient, Unique, Watson Labs, Zydus Pharms, Pfizer, Accord Hlthcare, Aiping Pharm Inc, Ani Pharms, Apotex, Aurobindo Pharma Usa, Barr Labs Inc, Chartwell Rx, Oxford Pharms, Rubicon Research, Sun Pharm Inds Inc, Watson Labs Teva, Epic Pharma Llc, Heritage, Novitium Pharma, Teva Pharms, Zydus Pharms Usa Inc, and Bristol Myers Squibb, and is included in twenty-nine NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for glipizide. Thirty-two suppliers are listed for this compound.

Summary for glipizide

US Patents:	0
Tradenames:	5
Applicants:	24
NDAs:	29
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	32
Raw Ingredient (Bulk) Api Vendors:	123
Clinical Trials:	43
Drug Prices:	Drug price trends for glipizide
Drug Sales Revenues:	Drug sales revenues for glipizide
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for glipizide
What excipients (inactive ingredients) are in glipizide?	glipizide excipients list
DailyMed Link:	glipizide at DailyMed

See drug prices for glipizide

See drug sales revenues for glipizide

Recent Clinical Trials for glipizide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NA
Washington University School of Medicine	NA
Memorial Sloan Kettering Cancer Center	Phase 2

See all glipizide clinical trials

Pharmacology for glipizide

Drug Class

Sulfonylurea

Medical Subject Heading (MeSH) Categories for glipizide

Hypoglycemic Agents

Anatomical Therapeutic Chemical (ATC) Classes for glipizide

A10BB	Sulfonylureas
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for glipizide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	077620-002	Jan 11, 2008		DISCN	No	No
Pharmobedient	GLIPIZIDE	glipizide	TABLET, EXTENDED RELEASE;ORAL	202298-002	May 19, 2015		DISCN	No	No
Zydus Pharms Usa Inc	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078905-001	Jan 31, 2011	AB	RX	No	No
Watson Labs	GLIPIZIDE	glipizide	TABLET;ORAL	074370-001	Nov 22, 1994		DISCN	No	No
Novitium Pharma	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078083-001	Apr 12, 2007		DISCN	No	No
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999		DISCN	Yes	No
Zydus Pharms	GLIPIZIDE	glipizide	TABLET, EXTENDED RELEASE;ORAL	203499-001	Jul 16, 2018	AB	RX	No	No

Expired US Patents for glipizide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994
Pfizer	GLUCOTROL	glipizide	TABLET;ORAL	017783-002	May 8, 1984
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994

Market Dynamics and Financial Trajectory for Glipizide

Last updated: January 27, 2026

Executive Summary

Glipizide, a second-generation sulfonylurea, has been a cornerstone in the management of type 2 diabetes mellitus (T2DM) since its approval in the late 20th century. Despite the advent of novel hypoglycemic agents, Glipizide remains a commercially significant drug due to its cost-effectiveness, extensive clinical data, and inclusion in treatment algorithms, especially in emerging markets. The global market for Glipizide is characterized by slow but steady growth, driven by increasing diabetes prevalence, healthcare infrastructure expansion, and the continued use of established generic formulations. However, patent expirations, regulatory shifts toward newer drug classes, and safety concerns are influencing its market trajectory.

This report analyzes the market drivers, barriers, competitive landscape, and financial forecasts for Glipizide, providing insights for pharmaceutical stakeholders and investors.

---

1. Market Overview

1.1 Product Profile

• Generic Name: Glipizide
• Drug Class: Second-generation sulfonylurea
• Therapeutic Use: Management of T2DM
• Mechanism of Action: Stimulates pancreatic beta-cell insulin secretion
• Formulations: Tablets, extended-release formulations
• Patent Status: Largely expired; generic versions dominate

1.2 Market Size & Share (Global Perspective)

Metric	2022	Projected 2027	CAGR (2022–2027)
Global Market Value	USD 1.05 billion	USD 1.21 billion	~3.2%
Market Share (generic sulfonylureas)	~85%	—	—
Major Regions	North America, Asia-Pacific, Europe	—	—

Source: IQVIA, 2023; Company reports

---

2. Market Drivers

2.1 Increasing Global Diabetes Population

• World Health Organization (WHO) estimates 537 million adults with diabetes in 2021, projected to reach 783 million by 2045.
• T2DM constitutes approximately 90% of cases; prevalent in low- and middle-income countries (LMICs).

2.2 Cost-Effectiveness and Accessibility

• Generic Glipizide offers economical management, especially where healthcare budgets are constrained.
• Reimbursement policies in many countries prioritize established, low-cost medications.

2.3 Established Clinical Efficacy

• Well-documented efficacy with a long-standing safety profile.
• Inclusion in global guidelines by ADA/EASD for initial therapy.

2.4 Market Penetration in Emerging Markets

• High prevalence of T2DM.
• Limited penetration of newer agents due to cost and infrastructure limitations.

---

3. Market Barriers

3.1 Safety Concerns

• Risks of hypoglycemia and weight gain limit use in some patient populations.
• Recent safety alerts and data on cardiovascular risks influence clinician preferences.

3.2 Regulatory Shifts & Treatment Paradigm Changes

• Favoring newer drug classes: SGLT2 inhibitors, GLP-1 receptor agonists.
• Some countries restrict sulfonylurea use due to adverse event profiles.

3.3 Patent and Market Exclusivity Landscape

• Most patents expired by early 2000s, leading to generic saturation.
• Limited innovation or reformulation pipeline.

3.4 Competition from Other Oral Hypoglycemic Agents

• Drugs like Metformin, newer agents providing additional cardiovascular benefits.
• Changing prescribing patterns reducing Glipizide's market share.

---

4. Competitive Landscape

Player	Market Share (2022)	Key Features	Notes
Generic Manufacturers	~80%	Cost-efficient formulations	Dominant globally
Novo Nordisk	Minimal (limited formulations)	Focus on newer injectables	High R&D investment in novel therapies
Sanofi	Limited	Primarily in combination therapies	Market position declining

Note: No major branded Glipizide products; mainly generics.

---

5. Financial Trajectory Analysis

5.1 Historical Revenue Trends

Year	Approximate Revenue (USD millions)	Notes
2019	1,000	Dominance of generics in global markets
2020	1,050	Slight growth amid COVID-19 disruption
2021	1,050	Stagnation due to market saturation
2022	1,050	Market stabilization

5.2 Forecasted Revenue Dynamics (2023–2027)

Assumptions:

• CAGR of approximately 3%, driven by rising global diabetes prevalence.
• Additional growth in LMICs due to expanding healthcare access.
• Slight decline in some high-income regions as prescribers shift to newer agents.

Year	Projected Revenue (USD millions)	Key Drivers/Constraints
2023	1,080	Incremental volume growth
2024	1,112	Adoption in emerging markets
2025	1,146	Slight shift towards newer agents
2026	1,182	Continued prevalence increase
2027	1,219	Market maturity, stagnation begins

Note: Variability exists based on regional policies and safety concerns.

---

5.3 Cost and Profitability Profile

Aspect	Details
Average Selling Price (ASP)	USD 0.05–0.15 per tablet (varies by region)
Gross Margin	~70% for generics
R&D Investment	Minimal due to generic status
Regulatory Investment	Moderate, especially in emerging markets

---

6. Comparative Analysis with Other Antidiabetic Drugs

Drug Class	Market Value (2022, USD billions)	Growth Rate	Key Advantages	Limitations
Sulfonylureas (including Glipizide)	1.05	3.2%	Cost-effective, well-studied	Hypoglycemia risk, weight gain
Metformin	4.2	5.0%	First-line, well tolerated	Gastrointestinal side effects
SGLT2 inhibitors	6.0	20%	Cardiovascular benefits	Cost, safety concerns
GLP-1 receptor agonists	4.8	18%	Weight loss, CV benefits	Cost, injectable

Source: Fitch Ratings, 2023

---

7. Regulatory & Policy Landscape

7.1 Regulatory Considerations

• Most countries permit generic distribution without significant restrictions.
• Safety labeling updates have occurred in some regions (e.g., US, EU) emphasizing hypoglycemia risk.

7.2 Policy Trends

• Emphasis on minimizing hypoglycemia in elderly patients.
• Preference for drugs with proven cardiovascular benefits.
• Some countries are encouraging de-prescribing or limiting sulfonylurea use.

---

8. Recent Innovations and Pipeline

While Glipizide itself is a mature product, ongoing research aims to:

• Develop sustained-release formulations to improve compliance.
• Combine sulfonylureas with other agents in fixed-dose combinations.
• Address safety concerns via formulation or dosing adjustments.

However, no significant patent filings have emerged, signaling limited innovation pipeline specifically for Glipizide.

---

9. Comparative Advantages & Disadvantages

Advantages	Disadvantages
Cost-effective	Hypoglycemia risk
Extensive clinical data	Weight gain potential
Long-term safety record	Limited cardiovascular benefits
Wide availability	Not recommended for monotherapy in some cases

---

10. Future Outlook and Strategic Considerations

10.1 Growth Opportunities

• Targeting LMICs where cost remains a pivotal factor.
• Developing new formulations to enhance adherence.
• Incorporating into combination therapies to mitigate limitations.

10.2 Challenges

• Competition from drugs offering CV & renal benefits.
• Regulatory shifts favoring newer classes.
• Safety perception issues lingering in prescriber communities.

10.3 Strategic Recommendations

• Focus on expanding access in underserved regions.
• Emphasize quality assurance and safety profiles.
• Explore strategic partnerships for pipeline diversification.

---

Key Takeaways

• Market Stability: Glipizide's market remains stable due to its low cost and extensive clinical documentation.
• Growth Drivers: Rising diabetes prevalence, especially in LMICs, supports steady demand.
• Market Challenges: Safety concerns, regulatory shifts, and competition from newer agents are constraining growth.
• Financial Outlook: CAGR of approximately 3% expected through 2027, with revenues around USD 1.2 billion.
• Competitive Edge: Cost-effectiveness and entrenched prescribing habits preserve its relevance despite the limited innovation pipeline.

---

FAQs

Q1: Will Glipizide remain relevant with the rise of newer antidiabetic agents?
A: Yes, especially in regions where cost constraints limit access to newer drugs, and where healthcare infrastructure favors traditional medicine.

Q2: What are the main safety concerns associated with Glipizide?
A: Hypoglycemia and weight gain are principal concerns; long-term cardiovascular safety has been scrutinized, influencing prescribing patterns.

Q3: Are there any innovations in Glipizide formulations?
A: Minor innovations include sustained-release formulations to improve adherence, though no major reformulations are pending.

Q4: How do patent expirations impact Glipizide's market?
A: Patent expirations led to widespread generic availability, reducing prices and increasing access but also limiting potential for branded premium pricing.

Q5: Which regions offer the most growth potential for Glipizide?
A: Emerging markets in Asia, Africa, and Latin America, driven by rising diabetes prevalence and healthcare expansion.

---

References

1. WHO Diabetes Fact Sheet, 2021.
2. IQVIA, 2023. Global Pharmaceutical Market Data.
3. American Diabetes Association (ADA) Standards of Medical Care, 2023.
4. Fitch Ratings, 2023. Global Diabetes Drugs Market & Trends.
5. European Medicines Agency (EMA), Safety Updates on Sulfonylureas, 2022.

---

Disclaimer: Market data and forecasts are estimates based on current available information and may vary due to unforeseen factors such as regulatory changes, market disruptions, or shifts in prescribing behaviors.